



SONI MEDICARE LTD.

38, Kanota Bagh, Jawahar Lal Nehru Marg, JAIPUR-302 004 INDIA
CIN No:- L51397RJ1988PLC004569
Telephone : (0141) 5163700, Fax : (0141) 2564392
E-mail : sonihospital@sonihospitals.com

Date: 13th February, 2020

To,
The Manager (Department of Corporate Affairs)
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai- 400001

BSE Scrip Code: - 539378 Scrip ID: - SML

Sub: Submission of Unaudited Financial Results for the quarter and nine months ended 31st December 2019

Dear Sir/Mam

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on Thursday, 13th February, 2020 have consider, approved and took on records the Unaudited Financial Results of the company for the quarter and the nine months ended 31st December 2019 along with the limited review report auditors.

A copy of the results along with the limited review report auditors is enclosed herewith.


Kindly acknowledge the receipt.

Thanking You

**Yours Faithfully,
For SONI MEDICARE LIMITED**


**Sweety Mamodia
(Company Secretary & Compliance Officer)**





A. NATANI & CO.

CHARTERED ACCOUNTANTS

Room No. 7, IInd Floor, Samod Tower, Dudu Bagh,


S.C.Road, Jaipur - 302 001

Phone No. : 4037253 M. No. : 98290-50994

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
To The Board of Directors of Soni Medicare Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("The Statement") of **SONI MEDICARE LIMITED** ("The Company") for the quarter and nine months ended 31st December 2019, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, as amended.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making enquiries, primarily of the company's personnel responsible for financials and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying unaudited Statement results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Natani & Co.
Chartered Accountants,
FRN 1007347C


(CA Ashok Kumar Natani)
Partner

M.No. 074692



Place : Jaipur

Dated : 13-02-2020

UDIN: 20074692AAAAAC4319



SONI MEDICARE LTD.

38, Kanota Bagh, Jawahar Lal Nehru Marg, JAIPUR-302 004 INDIA
 CIN No:- L51397RJ1988PLC004569
 Telephone : (0141) 5163700, Fax : (0141) 2564392
 E-mail : sonihospital@sonihospitals.com

SONI MEDICARE LIMITED
CIN: L51397RJ1988PLC004569
Registered Office: 38, Kanota Bagh, Jawahar Lal Nehru Marg, Jaipur

Statement of Standalone Unaudited Financial Results for the Quarter/Period ended 31st December, 2019

Particulars	Quarter Ended			Nine months ended		(Rs. In lacs)
	31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	Year Ended 31.03.2019 (Audited)
	I. Revenue from operations					
II. Other Income	357.97	440.15	389.45	1,201.33	1,049.54	1,466.62
III. Total Revenue (I + II)	10.74	3.36	5.34	17.75	15.94	24.36
IV. Expenses:	368.71	443.52	394.79	1,219.08	1,065.48	1,490.98
Cost of Material Consumed						
Changes in inventory of finished goods	68.11	67.44	50.19	195.74	110.63	149.86
Purchase of Traded Goods						
Employee benefits expense						
Finance costs	102.26	112.73	98.91	327.28	268.39	391.19
Depreciation and amortization expense	17.73	15.14	15.89	48.30	39.81	53.18
Other expenses	18.97	18.74	17.97	56.03	53.92	75.70
Total Expenses	207.47	224.97	201.62	646.83	628.80	881.16
V. Profit before exceptional & extraordinary items & tax (III - IV)	414.55	439.01	384.58	1,274.18	1,101.55	1,551.09
VI. Exceptional Items/Prior Period	-45.84	4.51	10.21	-55.10	-36.07	-60.11
VII. Profit before tax (V - VI)	0.02	0.56	-	0.61	-	-
VIII. Tax expense:	-45.86	3.95	10.21	-55.72	-36.07	-60.11
(1) Current tax						
(2) Deferred tax						
IX. Profit/(Loss) for the period (VII - VIII)						6.86
X. Other Comprehensive Income	-45.86	3.95	10.21	-55.72	-36.07	-66.97
XI. Total comprehensive income						
Paid Up Equity Share Capital (Face Value Rs. 10 each)	-45.86	3.95	10.21	-55.72	-36.07	-66.97
Basic and diluted earnings per share (in Rs.)	426.49	426.49	426.49	426.49	426.49	426.49
(1) Basic						
(2) Diluted	-1.08	0.09	0.24	-1.31	-0.85	-1.57
	-1.08	0.09	0.24	-1.31	-0.85	-1.57

NOTES:

- In Terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulaion, 2015, the standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the company in the Board Meeting held on February 13, 2020. The Statuory Auditors of the company have conducted limited review of these financial results.
- The company has adopted Indian Accounting Standards (Ind AS) from April 1, 2017 and accordingly the above financial results for the quarter ended 31st December, 2019 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with relevent rules issued thereunder and accordingly figures for the previous periods have been regrouped/reclassified.

Particulars	Quarter Ended			Nine months Ended		Year ended
	31.12.2019	30.09.2019 (Unaudited)	31.12.2018	31.12.2019	31.12.2018	31.03.2019
A. Sale of Products (Gross)						
B. Excise Duty	357.97	440.15	389.45	1,201.33	1,049.54	1,466.62
C. Sale of Products excluding Excise Duty (Net)						
	357.97	440.15	389.45	1,201.33	1,049.54	1,466.62

3. The previous period figures have ben regrouped/ rearranged wherever necessary.

By the order of the Board
 For SONI MEDICARE LIMITED



BIMARL ROY SONI
 Managing Director
 DIN:00716246

Date: 13-02-2020
 Place: Jaipur